GSK gets US FDA nod for Benlysta (Belimumab):
GSK Gets US FDA Nod For Benlysta. Benlysta is the first and only biological drug approved for adults and children who suffers from Lupus or Lupus Nephritis.
Lupus Nephritis is a serious inflammation of the kidney caused by Lupus, and at the end stage can lead to Kidney disease, and require dialysis, or a kidney transplant.
GSK has announced that the USFDA has approved Benlysta (Belimumab) for the treatment of active Lupus Nephritis in the age group of 5-17 yrs children.
Also Read:
- Zydus Get a USFDA nod for antifungal medication
- Dr.Reddys launched a generic version of Nexavar (Sorafenib)
- Glenmark gets USFDA nod Successfully for this drug
- What is Clinical Trial in Pharma?
- What is a phase 0 clinical trial in pharma?
- The Practices with data integrity risk (DI Risk)
- What are stability chambers in pharma?
- Clinical data management Interview Q&A
Refer YT Channels: Pharmabeej
